EX-23.1 2 tm249520d1_ex23-1.htm EXHIBIT 23.1

Exhibit 23.1

 

 

Consent of Independent Registered Public Accounting Firm

 

 

We consent to the incorporation by reference in this Registration Statement on Form S-1 and related Prospectus of Cyclacel Pharmaceuticals, Inc. of our report dated March 21, 2024, relating to the consolidated financial statements of Cyclacel Pharmaceuticals, Inc. and subsidiaries, appearing in the Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the year ended December 31, 2023.

 

We also consent to the reference to our firm under the heading “Experts” in such Prospectus.

 

/s/ RSM US LLP

 

New York, New York

March 22, 2024